Keyphrases
Antibody-drug Conjugate
16%
CD30
16%
CD69
33%
Chemoradiotherapy
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Classic Hodgkin Lymphoma
100%
Conventional Chemotherapy
16%
Current Treatment
16%
Galectin-1 (Gal-1)
16%
Healthy Tissue
16%
High Survival
16%
HLA-II
16%
Hodgkin
100%
Hodgkin Lymphoma Survivors
16%
Immune Cells
33%
Interaction Strength
16%
Less Toxic
16%
Long-term Adverse Effects
16%
LRP8
16%
Lymphoma Patients
16%
NRXN3
16%
PD-1/PD-L1 Axis
16%
Pediatric
33%
Pediatric Hodgkin Lymphoma
100%
Potential Interaction
16%
Putative Drug Targets
16%
Quality of Life
16%
RNAscope
16%
Single-cell RNA Sequencing (scRNA-seq)
100%
Surface Proteins
16%
Survival Rate
16%
T Cell Subtypes
100%
T Cells
33%
Targeted Therapy
16%
Therapeutic Target
16%
TNFRSF8
16%
Tumor
83%
Tumor Tissue
16%
Tumor-immune Interaction
16%
Medicine and Dentistry
Cell Interaction
16%
Cell Surface Protein
16%
Chimeric Antigen Receptor T-Cell
16%
Classical Hodgkin Lymphoma
100%
Conjugate
16%
Galectin 1
16%
Hodgkin's Lymphoma
100%
Immunocompetent Cell
50%
Neoplasm
66%
Pediatrics
100%
Programmed Death-Ligand 1
16%
Quality of Life
16%
Radiation Therapy
16%
RNA Sequence
100%
Side Effect
16%
Survival Rate
16%
T Cell
100%
Targeted Therapy
16%
Tumor
50%
Immunology and Microbiology
CD69
66%
Cell Interaction
33%
Cell Surface
33%
Chimeric Antigen Receptor T-Cell
33%
Conjugate
33%
Galectin 1
33%
Immunocompetent Cell
100%
LAG3
66%
Programmed Death-Ligand 1
33%
RNA Sequence
100%
Survival Rate
33%
T Cell
100%
